Robert Rothman, MD
Ophthalmology · Bethpage, NYNPI 1689672966
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $191,619 of the $231,220 with a category attached, or 82.9%. AbbVie accounts for 77.4% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $80,829 and has fallen 98.3% since, to $1,376 in 2025. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 470 payments — averaging $491.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$179K
- Aerie Pharmaceuticals, Inc.$39K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$5K
- Bausch & Lomb Americas Inc.$3K
- Alcon$1K
- Glaukos Corporation$701
- plus $2K from 18 others
Across 1 payment — averaging $1656.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2K
What the payments were for
- Consulting fees$7,3503%
- Speaking & faculty fees$191,61983%
- Travel & lodging$19,1178%
- Food & beverage$13,0896%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 290 | $179,030 |
| Aerie Pharmaceuticals, Inc. | 36 | $38,763 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $5,489 |
| Bausch & Lomb Americas Inc. | 14 | $3,448 |
| Alcon | 46 | $1,304 |
| Glaukos Corporation | 7 | $701 |
| NEW World Medical,inc. | 6 | $657 |
| Oyster Point Pharma, Inc. | 9 | $344 |
| Kala Pharmaceuticals, Inc. | 7 | $232 |
| Biotissue Holdings Inc. | 5 | $201 |
| Novartis | 12 | $196 |
| Sight Sciences, Inc. | 9 | $175 |
| Polaris Technology Solutions LLC | 1 | $157 |
| Tarsus Pharmaceuticals, Inc. | 1 | $113 |
| Iridex Corporation | 1 | $99 |
| Sun Pharmaceutical Industries Inc. | 4 | $91 |
| Ocular Therapeutix, Inc. | 3 | $56 |
| Harrow Eye, LLC | 1 | $33 |
| Rayner Intraocular Lenses Limited | 1 | $25 |
| Eyevance Pharmaceuticals LLC | 1 | $25 |
| Rxsight Inc | 1 | $22 |
| Ivantis, Inc | 1 | $22 |
| Thea Pharma Inc. | 1 | $20 |
| Amgen | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIGAN$98,089
- DURYSTA$57,967
- COMBIGAN$40,055
- Rocklatan$38,455
- Rhopressa$38,237
- VYZULTA$8,325
- ALPHAGAN P$4,851
- VUITY$2,031
- iDoseTR$342
- XEN$285
- Ahmed Glaucoma Valve$268
- Kahook Dual Blade$268
- iStent Infinite$181
- iStent inject W$150
- PanOptix$149
- XEN GLAUCOMA TREATMENT SYSTEM$128
- MIEBO$125
- XIIDRA$125
- TYRVAYA$120
- INVELTYS$119
How this compares
$231,220 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 462 | $300,554 |
| Phospholine IodideEchothiophate Iodide | 100 | $252,488 |
| RhopressaNetarsudil Mesylate | 166 | $117,550 |
| VyzultaLatanoprostene Bunod | 128 | $82,278 |
| CombiganBrimonidine Tartrate/Timolol | 134 | $78,044 |
| RocklatanNetarsudil Mesylat/Latanoprost | 92 | $68,234 |
| Alphagan PBrimonidine Tartrate | 98 | $51,693 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 118 | $38,198 |
| Brinzolamide | 162 | $35,423 |
| Brimonidine Tartrate | 275 | $34,319 |
| Travoprost | 91 | $29,185 |
| AzoptBrinzolamide | 34 | $21,399 |
| Pilocarpine Hcl | 243 | $14,689 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 55 | $13,368 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 522 | $10,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $179,030 | $430,291694 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $38,763 | $185,784258 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $3,448 | $82,278128 claims |
| AlconSimbrinza, Azopt | $1,304 | $59,598152 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Istalol | $5,489 | $12,28032 claims |
| Kala Pharmaceuticals, Inc.Inveltys | $232 | $8,11326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Bethpage
- David RubaltelliBrooklyn$8.9M
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Jonathan JonischGreat Neck$726K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.